Abstract: The present invention relates to a natural sweetening composition comprising Luo Han Guo concentrate in an amount of 0.1 to 95% by weight and use in beverage, food, pharmaceutical, oral, dietetic, veterinary or tobacco products thereof.

Abstract: This invention is a novel pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof in combination with a proton pump inhibitor for use in the antithrombotic treatment with preventing or reducing the risk of a gastrointestinal disorder.

Abstract: This invention is about a blister which is an integral component of a dry powder inhaler and is structured from a base sheet and a lid sheet comprising at least two layers made from polymeric materials and flat aluminium foil, wherein the cavity that is used for storing the inhalable formulation is in the volume range of 5 to 19.8 mm3 and the cavity is filled up to 25-100%.

Abstract: The present invention relates to a natural sweetening composition comprising Luo Han Guo concentrate in an amount of 0.1 to 95% by weight and use in beverage, food, pharmaceutical, oral, dietetic, veterinary or tobacco products thereof.

Abstract: The present invention relates to a natural sweetening composition comprising apple concentrate having a median particle size (d50) greater than 100 ?m and Luo Han Guo concentrate having a median particle size (d50) greater than 1 ?m and use in beverage, food, pharmaceutical, oral, dietetic, veterinary or tobacco products thereof.

Abstract: The present invention relates to a novel process used for the preparation of dry powder formulations for inhalation.

Abstract: The present invention relates to a natural sweetening composition comprising Luo Han Guo concentrate having a median particle size (d50) greater than 1 ?m and use in beverage, food, pharmaceutical, oral, dietetic, veterinary or tobacco products thereof.

Abstract: The present invention relates to stable oral topical aqueous pharmaceutical compositions comprising flurbiprofen or pharmaceutically acceptable salts thereof and dexpanthenol or pharmaceutically acceptable salts thereof. Furthermore the present invention also relates to stable oral topical aqueous pharmaceutical compositions comprising flurbiprofen or pharmaceutically acceptable salts thereof and dexpanthenol or pharmaceutically acceptable salts thereof and chlorhexidine or pharmaceutically acceptable salts thereof. More particularly, the present invention relates to stable oral topical aqueous pharmaceutical compositions of these combinations having desired levels of solubility, enhanced taste and absorption from mucosal surface, wherein the pH of the solution is between 6 and 7.

Abstract: The present invention relates to a pharmaceutical formulation comprising an immediate release phase comprising an effective amount of flurbiprofen and a controlled release phase comprising an effective amount of tramadol and pharmaceutically acceptable excipients.

Abstract: The present invention relates to a pharmaceutical composition comprising flurbiprofen and tramadol or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient.

Abstract: The present invention relates to a novel process used for the preparation of dry powder formulations for inhalation.

Abstract: A pharmaceutical combination comprising sitagliptin or a pharmaceutically acceptable salt thereof in combination with a sulfonylurea.

Abstract: The present invention relates to a novel pharmaceutical composition comprising zaltoprofen or a pharmaceutically acceptable salt thereof in combination with muscle relaxants with anti-inflammatory, analgesic and myorelaxant activity.

Abstract: This invention is a novel pharmaceutical composition comprising sofosbuvir and ribavirin as active agents with at least one pharmaceutically acceptable excipient, wherein at least one of the active agents is in the form of controlled release, for use in the treatment of hepatitis C virus infections, chronic hepatitis C, hepatocellular carcinoma or patients with end-stage liver disease awaiting liver transplantation.

Abstract: This invention is a novel pharmaceutical composition comprising loxoprofen or a pharmaceutically acceptable salt thereof in combination with gamma-aminobutiric acid receptor agonist or a pharmaceutically acceptable salt thereof with anti-inflammatory, analgesic and myorelaxant activity.

Abstract: The present invention relates to a novel process used for the preparation of dry powder formulations for inhalation.

Abstract: The present invention relates to a novel process used for the preparation of dry powder formulations for inhalation.

Abstract: This invention is a novel modified release pharmaceutical composition comprising sofosbuvir and ribavirin and at least one pharmaceutically acceptable excipient for use in the treatment of hepatitis C virus infections, chronic hepatitis C (CHC), hepatocellular carcinoma or patients with end-stage liver disease awaiting liver transplantation.

Abstract: This invention is a novel pharmaceutical composition comprising sofosbuvir and ribavirin and at least one pharmaceutically acceptable excipient for use in the treatment of hepatitis C virus infections, chronic hepatitis C (CHC), hepatocellular carcinoma or patients with end-stage liver disease awaiting liver transplantation.

Abstract: This invention is a novel pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof in combination with a proton pump inhibitor for use in the antithrombotic treatment with preventing or reducing the risk of a gastrointestinal disorder.